KRAS/NRAS Mutations Predict Panitumumab Nonresponsiveness in Metastatic CRC
Panitumumab plus second-line FOLFIRI chemotherapy is unlikely to improve outcomes in mCRC tumors harboring RAS mutations.
GI Cancers Symposium 2014
Neoadjuvant Capecitabine Equivalent to 5-FU for Rectal Cancer
Oral capecitabine plus neoadjuvant radiation offers equivalent outcomes and toxicity profiles compared to 5-fluorouracil (5-FU) plus radiation.
CAPTEM Offers Long-lasting Neuroendocrine Tumor Control
Combination capecitabine and temozolomide offer long-lasting neuroendocrine tumor control for patients whose tumors haven’t responded to standard therapy.
Second-Line Ramucirumab Plus Paclitaxel Improves Survival in Metastatic Gastric Cancer
Compared with paclitaxel alone, combining ramucirumab with paclitaxel increased survival in metastatic gastric cancer.
Vaccine Combination Improves Survival in Metastatic Pancreatic Cancer
The combination of two anticancer vaccines, as compared with one vaccine, doubled overall survival in metastatic pancreatic cancer.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in GI Cancers Symposium 2014
Loading... 
Loading...